Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study

被引:5
作者
Alejos, Belen [1 ]
Suarez-Garcia, Ines [2 ]
Rava, Marta [1 ]
Bautista-Hernandez, Azucena [3 ]
Gutierrez, Felix [4 ]
Dalmau, David [5 ]
Sagastagoitia, Inigo [6 ]
Rivero, Antonio [7 ]
Moreno, Santiago [8 ]
Jarrin, Inma [1 ]
机构
[1] Inst Hlth Carlos III, Ctr Nacl Epidemiol, Madrid, Spain
[2] Hosp Infanta Sofia, Madrid, Spain
[3] Hosp Univ La Princesa, Madrid, Spain
[4] Hosp Gen Univ Elche, Elche, Spain
[5] Hosp Univ Mutua Tarrassa, Tarrasa, Spain
[6] Hosp Clin San Carlos, Madrid, Spain
[7] Hosp Reina Sofia, Cordoba, Spain
[8] Hosp Univ Ramon y Cajal IRYCIS, Madrid, Spain
关键词
HIV-INFECTED PATIENTS; HUMAN-IMMUNODEFICIENCY-VIRUS; ONCE-DAILY DOLUTEGRAVIR; NAIVE ADULTS; THERAPY; RALTEGRAVIR; PERCENTAGE; RATIO; NORMALIZATION; SUPPRESSION;
D O I
10.1093/jac/dkaa246
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: We compared 48week effectiveness and safety of first-line antiretroviral regimens. Methods: We analysed HIV treatment-naive adults from the Cohort of the Spanish HIV/AIDS Research Network (CoRIS) starting the most commonly used antiretroviral regimens from 2014 to 2018. We used multivariable regression models to assess the impact of initial regimen on: (i) viral suppression (VS) (viral load <50 copies/mL); (ii) change in CD4 cell count; (iii) CD4/CD8 normalization (>0.4 and >1); (iv) CD4 percentage normalization (>29%); (v) multiple T-cell marker recovery (MTMR: CD4>500cells/mm(3) plus CD4 percentage >29% plus CD4/CD8>1); (vi) lipid, creatinine and transaminase changes; and (vii) discontinuations due to adverse events (AE). Results: Among 3945 individuals analysed, the most frequently prescribed regimens were ABC/3TC/DTG (34.0%), TAF/FTC/EVG/CBT (17.2%), TDF/FTC + DTG (11.9%), TDF/FTC/EVG/CBT (11.7%), TDF/FTC/RPV (11.5%), TDF/FTC + bDRV (8.3%) and TDF/FTC + RAL (5.3%). At 48weeks, 89.7% of individuals achieved VS with no significant differences by initial regimen. CD4 mean increase was 257.8 (249.3; 266.2) cells/mm(3), and it was lower with TAF/FTC/EVG/CBT and TDF/FTC/RPV compared with ABC/3TC/DTG. CD4 percentage normalization was less likely with TAF/FTC/EVG/CBT, and MTMR was less likely with TAF/FTC/EVG/CBT and TDF/FTC + RAL. The proportion of discontinuations due to AE was higher with TDF/FTC + bDRV (9.7%), followed by TDF/FTC/EVG/CBT (9.5%) and TDF/FTC + DTG (7.9%). Compared with ABC/3TC/DTG, cholesterol and LDL mean increases were higher with TAF/FTC/EVG/CBT and lower with TDF/FTC + DTG, TDF/FTC/RPV and TDF/FTC + RAL. Higher mean increases in triglycerides were significantly associated with TAF/FTC/EVG/CBT. Regimens containing DTG showed higher creatinine increases. Conclusions: The significantly greater immunological response and safety of some combinations may be useful for making decisions when initiating treatment.
引用
收藏
页码:3004 / 3014
页数:11
相关论文
共 30 条
[1]   Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors [J].
Alejos, Belen ;
Suarez-Garcia, Ines ;
Bisbal, Otilia ;
Antonio Iribarren, Jose ;
Asensi, Victor ;
Gorgolas, Miguel ;
Muga, Roberto ;
Moreno, Santiago ;
Jarrin, Inma ;
Jarrin, Inma ;
Dalmau, David ;
Luisa Navarro, Maria ;
Isabel Gonzalez, Maria ;
Luis Blanco, Jose ;
Garcia, Federico ;
Rubio, Rafael ;
Antonio Iribarren, Jose ;
Gutierrez, Felix ;
Vidal, Francesc ;
Berenguer, Juan ;
Gonzalez, Juan ;
Alejos, Belen ;
Hernando, Victoria ;
Moreno, Cristina ;
Iniesta, Carlos ;
Garcia Sousa, Luis Miguel ;
Sanz Perez, Nieves ;
Angeles Munoz-Fernandez, M. ;
Maria Garcia-Merino, Isabel ;
Consuegra Fernandez, Irene ;
Gomez Rico, Coral ;
Gallego De la Fuente, Jorge ;
Palau Concejo, Paula ;
Portilla, Joaquin ;
Merino, Esperanza ;
Reus, Sergio ;
Boix, Vicente ;
Giner, Livia ;
Gadea, Carmen ;
Portilla, Irene ;
Pampliega, Maria ;
Diez, Marcos ;
Carlos Rodriguez, Juan ;
Sanchez-Paya, Jose ;
Luis Gomez, Juan ;
Hernandez, Jehovana ;
Remedios Aleman, Maria ;
del Mar Alonso, Maria ;
Inmaculada Hernandez, Maria ;
Diaz-Flores, Felicitas .
PLOS ONE, 2019, 14 (08)
[2]  
[Anonymous], 2018, GUID US ANT AG AD AD
[3]   Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naive and -experienced patients [J].
Brehm, Thomas Theo ;
Franz, Marleen ;
Huefner, Anja ;
Hertling, Sandra ;
Schmiedel, Stefan ;
Degen, Olaf ;
Kreuels, Benno ;
zur Wiesch, Julian Schulze .
MEDICINE, 2019, 98 (32)
[4]   Incident AIDS or Death After Initiation of Human Immunodeficiency Virus Treatment Regimens Including Raltegravir or Efavirenz Among Adults in the United States [J].
Cole, Stephen R. ;
Edwards, Jessie K. ;
Hall, H. Irene ;
Brookhart, M. Alan ;
Mathews, W. Christopher ;
Moore, Richard D. ;
Crane, Heidi M. ;
Kitahata, Mari M. ;
Mugavero, Michael J. ;
Saag, Michael S. ;
Eron, Joseph J. .
CLINICAL INFECTIOUS DISEASES, 2017, 64 (11) :1591-1596
[5]   Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens [J].
Edwards, Jessie K. ;
Cole, Stephen R. ;
Hall, H. Irene ;
Mathews, W. Christopher ;
Moore, Richard D. ;
Mugavero, Michael J. ;
Eron, Joseph J. .
AIDS, 2018, 32 (02) :261-266
[6]   Adverse events of raltegravir and dolutegravir [J].
Elzi, Luigia ;
Erb, Stefan ;
Furrer, Hansjakob ;
Cavassini, Matthias ;
Calmy, Alexandra ;
Vernazza, Pietro ;
Gunthard, Huldrych ;
Bernasconi, Enos ;
Battegay, Manuel .
AIDS, 2017, 31 (13) :1853-1858
[7]  
European AIDS Clinical Society, 2018, EACS GUIDELINES VERS
[8]  
Fogli M, 2014, NEW MICROBIOL, V37, P75
[9]   CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts &gt;350 lymphocytes/mm3 [J].
Hulgan, T ;
Raffanti, S ;
Kheshti, A ;
Blackwell, RB ;
Rebeiro, PF ;
Barkanic, G ;
Ritz, B ;
Sterling, TR .
JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (06) :950-957
[10]   A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results [J].
Kennedy-Martin, Tessa ;
Curtis, Sarah ;
Faries, Douglas ;
Robinson, Susan ;
Johnston, Joseph .
TRIALS, 2015, 16